Hims & Hers Health, Inc.'s subscriber growth, Novo Nordisk partnership, and FDA pill approval could boost financials. Click ...

Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.

Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...

Hims & Hers Health ( HIMS) shares surged 8% Tuesday, a day after the health and wellness platform posted better-than-expected ...

The company reported adjusted earnings per share of $0.28 on revenue of $586 million – a significant rise compared to last ...

Hims & Hers on Tuesday announced a collaboration with drugmaker Novo Nordisk to bundle Wegovy and a Hims & Hers membership on ...

Hims & Hers Health Inc. (NYSE:HIMS) partners with Novo Nordisk to offer affordable weight-loss drug, positioning itself to ...

Hims & Hers Health Inc. posted better-than-expected first-quarter revenue as the company pivots away from making copycat ...

Him & Hers Health and Novo Nordisk are collaborating to offer weight-loss treatment, including access to Wegovy along with ...

Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply reduced price on several telehealth ...

Novo Nordisk said on Tuesday it was working with telehealth firms Hims & Hers , Ro and LifeMD to sell Wegovy, as it looks to ...

But Hims & Hers' shares fell in after-hours trading as second-quarter projections fell short of analysts' expectations. The ...